EUCTR2019-000261-21-FR
Active, not recruiting
Phase 1
A randomised, double-blind, placebo-controlled and parallel group trial to evaluate efficacy and safety of twice daily inhaled doses of BI 1265162 delivered by Respimat® inhaler as add-on therapy to standard of care over 4 weeks in patients with cystic fibrosis
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Cystic Fibrosis
- Sponsor
- Boehringer Ingelheim France
- Enrollment
- 98
- Status
- Active, not recruiting
- Last Updated
- 5 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Male or female patients / 12 years of age or older at screening;
- •2\. Documented diagnosis of cystic fibrosis including:
- •positive sweat chloride \= 60 mEq/L, by pilocarpine iontophoresis or
- •a genotype with 2 identifiable mutations consistent with cystic fibrosis accompanied by one or more clinical features with cystic fibrosis phenotype;
- •3\. FEV1 \= 40% and \= 90% of predicted values at screening and at predose at Visit 2 (randomisation).
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 21
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range 77
- •F.1\.3 Elderly (\>\=65 years) no
Exclusion Criteria
- •1\. Evidence of acute upper or lower respiratory tract infection within 4 weeks prior to randomisation based on investigator’s judgement;
- •2\. Pulmonary exacerbation requiring use of i.v./oral/inhaled antibiotics or oral corticosteroids within 4 weeks prior to randomisation;
- •3\. Women of childbearing potential
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 2
The effects of cannabidiol (CBD) on psychosocial stress, situational anxiety and nausea experienced in a virtual reality environmentPsychosocial stressSituational anxietyMotion sicknessCybersicknessMental Health - AnxietyMental Health - Other mental health disordersACTRN12623000872639niversity of Sydney74
Active, not recruiting
Phase 1
Tralokinumab monotherapy for adolescent subjects with moderate-to-severe atopic dermatitis - ECZTRA 6Atopic DermatitisMedDRA version: 20.0Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]EUCTR2017-005143-33-PLEO Pharma A/S301
Active, not recruiting
Phase 1
A study of mepolizumab (study medicine) as an add-on therapy in subjects with severe uncontrolled asthmaSubjects with severe asthmaMedDRA version: 17.1Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersTherapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]EUCTR2014-002513-27-ESGlaxoSmithKline, S.A.544
Active, not recruiting
Not Applicable
A randomised, double-blind, placebo-controlled, parallel-group, multicenterstudy to demonstrate improvement of symptoms of RLS in subjects withmoderate to severe idiopathic RLS with daytime symptoms who takeoxycodone/naloxone prolonged release (OXN PR) compared to subjects takingplacebo (PLA).Estudio multicéntrico, aleatorizado, con doble anonimato, controlado conplacebo, en grupos paralelos, para demostrar la mejoría de los síntomas delsíndrome de las piernas inquietas (RLS) en pacientes con RLS idiopático, demoderado a grave, con síntomas diurnos, que toman oxicodona/naloxona deliberación prolongada (OXN PR), comparados con el grupo tratado con placebo(PLA).Sindrome de Piernas inquietasRestless Legs SyndromeMedDRA version: 12.0Level: LLTClassification code 10058920Term: Restless legs syndromeEUCTR2009-011107-23-ESMundipharma Research GmbH & Co. KG300
Active, not recruiting
Phase 1
A study of mepolizumab (study medicine) as an add-on therapy in subjects with severe uncontrolled asthma.Subjects with severe asthmaMedDRA version: 19.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersTherapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]EUCTR2014-002513-27-EEGlaxoSmithKline Research & Development Ltd544